According to the National Cancer Institute, approximately 40.5% of Americans will be diagnosed with cancer at some point ...

There are relapsing-remitting and progressive types of MS, but the course is rarely predictable. Researchers still don’t fully understand the cause of MS or why the rate of progression is so ...

The rate of frailty among patients with multiple sclerosis (MS) ranges from 17% to 66% among ambulatory patients, and frailty among MS patients is linked to a host of complications. Read about the ...

Doctors divide speech problems into two types: aphasia and dysarthria. Dysarthria is more relevant to people living with MS. It’s tied ... Rely on others to be patient so you can speak as ...

A Phase 2 clinical trial testing obexelimab in adults with relapsing types of multiple sclerosis is now recruiting ...

There is currently no cure for Multiple Sclerosis (MS). Patients rarely do well with no therapy at all, and it is generally recommended that patients with a confident diagnosis of MS begin treatment ...

Less frequent Ocrevus infusions are just as effective in controlling MS, but may help limit the risk of side effects, per a ...

The study included 779 patients with MS and 3,116 controls with breast cancer ... have become a widely used therapeutic option for a broad range of tumor types, typically targeting pathways ...

Background Treatment options for patients suffering from progressive forms of multiple sclerosis (MS) remain inadequate. Mast cells actively participate in the pathogenesis of MS, in part because ...

Patients with relapsing remitting MS (RRMS) and primary progressive MS ... was higher for other DMTs versus ocrelizumab, across all types of administration (oral, injectable, and infusion).” ...